Results of your search: limit 6 to ((adult < 19 to 44 years > or middle age < 45 to 64 years > or "aged < 65 and over >" or "aged, 80 and over") and clinial trial)
Citations available: 30
Citations displayed: 1-10
Checked Box Citations in "Titles Display" format
Click in the boxes to select the first 2 references. 
Then scroll down the list of references to the Citation Manager

1. Anonymous.Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group [see comments]. [Clinical Trial. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial] Lancet. 352(9139):1498-504, 1998 Nov 7.   Abstract | Complete Reference

2. Anonymous. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS [see comments]. [Clinical Trial. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial] Lancet. 352(9139):1491-7, 1998 Nov 7. Abstract | Complete Reference

3. Trojano M. Avolio C. Ruggieri M. Defazio G. Giuliani F. Paolicelli D. Livrea P. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment. [Clinical Trial. Journal Article] Multiple Sclerosis. 4(3):183-7, 1998 Jun.   Abstract | Complete Reference

4. Rieckmann P. Altenhofen B. Riegel A. Kallmann B. Felgenhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. [Clinical Trial. Journal Article] Multiple Sclerosis. 4(3):178-82, 1998 Jun.   Abstract | Complete Reference

5. Martinez-Caceres EM. Rio J. Barrau M. Duran I. Borras C. Tintore M. Montalban X. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. [Clinical Trial. Journal Article. Randomized Controlled Trial] Annals of Neurology. 44(4):682-5, 1998 Oct.   Abstract | Complete Reference

6. Molyneux PD. Tofts PS. Fletcher A. Gunn B. Robinson P. Gallagher H. Moseley IF. Barker GJ. Miller DH. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Neurology, Neurosurgery & Psychiatry. 65(1):42-7, 1998 Jul.   Abstract| Complete Reference

7. Edwards S. Zvartau M. Clarke H. Irving W. Blumhardt LD. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Neurology, Neurosurgery & Psychiatry. 64(6):736-41, 1998 Jun.  Abstract | Complete Reference

8. Rio J. Nos C. Marzo ME. Tintore M. Montalban X. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS. [Clinical Trial. Journal Article. Randomized Controlled Trial] Neurology. 50(6):1910-2, 1998 Jun.   Abstract | Complete Reference (without Full Text) | Full Text

9. Ferrarini AM. Sivieri S. Bulian P. Buttarello M. Biasi G. Tavolato B. Gallo P. Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients. [Clinical Trial. Journal Article] Journal of Neuroimmunology. 84(2):213-7, 1998 Apr 15.   Abstract | Complete Reference

10. Hafler DA. Kent SC. Pietrusewicz MJ. Khoury SJ. Weiner HL. Fukaura H. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. [Clinical Trial. Journal Article] Annals of the New York Academy of Sciences. 835:120-31, 1997 Dec 19.  Abstract | Complete Reference

Complete Record

Next Citation(s)

 
Click on the Box label to get more information about the options

Citation Manager: Display, Save, or Email Citations
Citations Fields Citation Format Save Format Action
All on this page (10)
All in this set (30)
Selected (all pages)

and/or Range:
(Max: 30 citations)

 Citation only
Citation + Abstract
Citation + Abstract + Subject Headings
Complete Record 
Select Fields		 Ovid
BRS/Tagged
Reprint/Medlars
Include Search History 		 ASCII Text (DOS/Windows)
ASCII Text (Macintosh)
ASCII Text (Unix)		 Display Citations
Email Citations
Save Citations
Click on any
of the above
Action items to 
get more information

The Sort by: Primary Key default is by date (most recent citations first). The Sort by: Secondary Key default is alphabetical by author. You can change the default by using the drop down menus.

Copyright 1998 Ovid Technologies, Inc.

Biomedical Library Homepage  |  Site Index  |  Search this Site
Resources  |  Services  |  About the Library

Web address:     http://southmed.usouthal.edu/library/ref/ovid/print2.htm
Last Update:     2/14/02
To make comments, suggestions, or get more information, send e-mail to medlib@jaguar1.usouthal.edu or call (251)-414-8210.
© 1999 Duke University Medical Center